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background:  New evidence suggests that the bleeding advantage of bivalirudin over heparin seen in older trials has diminished. The 
current analysis identifies the new advances in percutaneous coronary intervention responsible for mitigating the hemostatic advantage of 
bivalirudin.
methods:  We used data from 18 randomized trials of 44,700 patients, of whom 5,072 underwent the transradial approach, 2,964 received 
a novel P2Y12 platelet inhibitor, 10,229 received ≤60 units heparin/kg; but 2,246 experienced major bleeding and 191 had definite stent 
thrombosis. Using Bayesian approaches, we used a normalizing factor α to down-weight older studies to identify advances that account for 
reduced bleeding differences.
results:  Overall, the risk of major bleeding was lower (posterior mean odds ratio [OR] 0.59, 95% Bayesian credible interval [BCI] 0.46-
0.74) but the risk of definite ST was higher (OR 1.74, 95% BCI 1.21-2.49) after using bivalirudin in place of heparin. An unweighted 
conjugate-normal model integrating results of older trials and new trials and using α=1.0 showed a persistent hemostatic advantage of 
bivalirudin (Figure). Older studies had to be down-weighted by 90% (α=0.10) to 99% (using α=0.01) to neutralize the bleeding advantage of 
bivalirudin, but this produced no effect on the risk of ST.
Conclusion:  The use of the transradial approach, novel P2Y12 platelet inhibitors, and low-dose heparin may have mitigated the bleeding 
advantage of bivalirudin over heparin in contemporary trials.
 
